Masnon Nurul-AinZuhratun Nazihah Khairul KamalWan-Hazabbah Wan HitamMaimunah Abdul Muna'aimFaizah Mohd Zaki2024-05-282024-05-2820212022-2-16Nurul-Ain M, Khairul Kamal ZN, Wan Hitam WH, Abd Munaaim M, Mohd Zaki F. Myelin Oligodendrocyte Glycoprotein (MOG) Optic Neuritis: A Case Series. Cureus. 2021 Apr 13;13(4):e14452. doi: 10.7759/cureus.144522168-81842034-810.7759/cureus.14452https://www.cureus.com/articles/56337-myelin-oligodendrocyte-glycoprotein-mog-optic-neuritis-a-case-serieshttps://oarep.usim.edu.my/handle/123456789/5417Myelin oligodendrocyte glycoprotein (MOG) antibody disease has been recognised as a distinct demyelinating disorder. Optic neuritis has been reported as the most common presentation and manifestation of this spectrum disorder. This is a case series of three MOG optic neuritis patients. Patients involved are female with disease onset ranging between 7- and 37-year-old. Most of these patients experienced symptoms of profound reduced visual acuity with eye pain. All three patients had optic disc swelling upon first presentation and they experienced at least one episode of bilateral simultaneous optic neuritis. Only one patient had demonstrable optic nerve enhancement on magnetic resonance imaging (MRI). Disease was confirmed through positive MOG antibody. Patients typically responded well to intravenous methylprednisolone (IVMP) during acute attack of optic neuritis. However, one patient had suboptimal response to IVMP after multiple relapses. We noted multiple relapses of optic neuritis are common in MOG patients. MOG optic neuritis is a devastating, but treatable condition. Aggressive treatment during acute optic neuritis attack and relapse prevention may favour a good visual prognosis in MOG antibody disease.endemyelinating diseases; myelin-oligodendrocyte glycoprotein (mog); optic neuritisArticle14134